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dihydrotestosterone in peripheral tissues (Longcope
1996). In females, androstenedione is produced by the
theca calls of the corpus luteum, and under these circumstances it is rapidly converted to estrogen and/or
progesterone. The production of androgens by theca
cells appears to be regulated by insulin and insulin-like
growth factors, explaining the association between
hyperinsulinaemia and hyperandrogenism observed in
women with polycystic ovarian syndrome (Lanzone et al.
1994, Nahum et al. 1995).

ABSTRACT
The pUfPose of this study was to examine the influence of
androstenedione supplementation on plasma testosterone,
cortisol, and cholesterol, mean arterial pressure (MAP), body
weight, organ weights, and bone mineral density (BMD) in
female rats. At age 10 weeks, an initial BMD measure was
made. Rats in the andro group (n = 13) received implants
designed to deliver 1 J.lg androstenedione per gram body wt per
day. Rats in the control group (n = 13) received similar
implants containing dextrose. After 8 weeks an arterial
catheter was surgically implanted. MAP was measured for 30
minutes during home cage rest and a blood sample was taken
for measurement of plasma cholesterol and testosterone. The
next day animals were exposed to a novel stress (immersion in
shoulder-deep, 37 ·C water) for 15 minutes. MAP was measured before, during, and after the stress, and blood samples
were taken for measurement of plasma cortisol. Animals were
then euthanized and a final BMD measurement was made.
The heart, liver, kidneys, adrenal glands, and ovaries were
excised and weighed. Plasma cholesterol was significantly
lower in the andro group, but there were no differences in MAP,
plasma testosterone, plasma cortisol, body weights, organ
weights, or BMD between groups.

Examination of the influence of supplemental androstenedione on plasma levels of testosterone and
changes in lean muscle mass and muscle strength have
primarily focused on males. A single 100 mg dose of
androstenedione failed to increase serum testosterone
concentration in males, and long term (8-12 weeks)
treatment with androstenedione did not enhance lean
body mass or muscle strength in males participating in
resistance training (King et al. 1999, Wallace et al.
1999). Ingestion of a single 100 mg dose of androstenedione in two healthy women, however, resulted in
4- and 7-fold increases in blood testosterone concentration (Mahesh and Greenblatt 1962), but information
about long term treatment with androstenedione on
lean body mass or muscle strength in females is lacking.

t t t
Androstenedione is one of many intermediate compounds in steroid biosynthesis in the adrenal glands and
the gonads. Cholesterol, the precursor for all steroid
hormones, is converted first into 20 a-hydroxycholesterol
by 20 a-hydroxylase and then into pregnenolone by
desmolase. Pregnenolone can enter various biochemical
pathways, resulting in the synthesis of mineralocorticoids (e.g., aldosterone), glucocorticoids (e.g., cortisol),
androgens (e.g., testosterone), and estrogens (e.g., estradiol-17P). Testosterone may be metabolized in the liver
to form 2a-, 16a-, and 6p-hydroxytestosterone, androstenedione, and 16a-hydroxyandrostenedione (Sugiyama
et al. 1994), and both testosterone and androstenedione
may be aromatized to estrogens or reduced to

The adverse effects oflong term anabolic steroid use
(and abuse) are well known and include infertility,
atrophy of the gonads, male pattern baldness in both
sexes, decrease in body fat in females, short stature
(when the steroid is taken during periods ofgrowth), left
ventricular hypertrophy, and liver tumors (National
Institute on Drug Abuse Research Report Series, 2000).
Long term treatment with androstenedione has been
shown to have negative effects on the cardiovascular
system. For example, serum high-density lipoprotein
cholesterol levels in males were decreased following long
term (8-12 weeks) treatment with androstenedione (King
17
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et al. 1999). Previous work (Alen and Rahkila 1988, Alen
et al. 1985, Costill et al. 1984, Haffner et al. 1983, Hurley
et al. 1984, Kuipers et al. 1991, Peterson and Fahey
1984) suggests that elevated plasma levels of androgens
are associated with an increased risk of cardiovascular
disease in males. The influence oflong term treatment
with androstenedione on serum cholesterol levels in
females is not known.
Cortisol stimulates gluconeogenesis by the liver,
mobilizes amino acids from nonhepatic tissues, and
mobilizes fatty acids from adipose tissues, enabling the
body to resist stress. Previous studies have demonstrated an acute increase in plasma cortisol levels following exercise (Chandler et al. 1994, Hakkinen and
Pakarinen 1993, Kraemer et al. 1993). The potential for
supplemental androstenedione to enhance cortisol levels during stressful situations, and thus enable the body
to cope more efficiency with the stressor, has not been
investigated.
The increased bone turnover in postmenopausal
women has been associated with decreased plasma levels of estrogen (Christiansen et al. 1982). There is
evidence that plasma levels of androstenedione and
testosterone are greater in premenopausal women compared with both peri- and postmenopausal women (Judd
and Fournet 1994), and in postmenopausal women a
positive relationship has been observed between oestradiol and testosterone levels and bone mineral density
(Murphy et al. 1992). Moreover, androstenedione has
been shown to protect against the development of
osteopenia in ovariectomized rats, mediating its effect
through androgen synthesis (Lea and Flanagan 1998).
The potential role, however, of supplemental androstenedione in the development of peak bone density has
not been investigated.
The purpose of this study was to examine the influence of long-term (10 weeks) treatment with androstenedione on plasma testosterone, cortisol, and cholesterol, mean arterial pressure (MAP), bone mineral density (BMD), body weight, and organ weights in female
rats. Body weight was measured as an index of growth,
and selected organs were weighed as indices of the
potential influence oflong term androstenedione treatment on the physiology of these organs. The hypotheses
ofthis study were as follows: 1) long-term administration of the supplement androstenedione will have no
influence on plasma levels of testosterone or cholesterol
in sedentary female Long Evans rats at rest; 2) longterm administration of the supplement androstenedione will have no influence on plasma levels of cortisol in
sedentary female Long Evans rats at rest or during
exposure to novel immersion stress; 3) long-term administration of the supplement androstenedione will have
no influence on the MAP of sedentary female Long

Evans rats at rest or during exposure to novel immersion
stress; 4) long-term administration of the supplement
androstenedione will have no influence on the BMD of
sedentary female Long Evans rats; 5) long-term administration of the supplement androstenedione will have
no influence on the growth (as measured by increase in
body weight) of sedentary female Long Evans rats; and
6) long-term administration of the supplement androstenedione will have no influence on the weight of the
heart, liver, kidneys, adrenal glands, or ovaries of sedentary female Long Evans rats.

METHODS
All methods were approved by the University of
Nebraska at Kearney (UNK) Institutional Animal Care
and Use Committee. Twenty-six female Long Evans
rats (originally derived from Charles River stock) born
between 06/04/99 and 06112199 in the UNK Copeland
Hall animalfacility were used in this study. At approximately 10 weeks of age, the rats were anesthetized with
a mixture of ketamine (100 mg/kg i.p.; K-2753, Sigma
Chemical Company, St. Louis, MO) and xylazine (20 mg/
kg i.p.; X-1251, Sigma Chemical Company, St. Louis,
MO) for measure of bone mineral density. Bone mineral
density (BMD) was measured by dual energy x-ray
absorptiometry(DPX-IQ®, LUNAR®Corporation, Madison, WI) using the forearm acquisition mode in the UNK
Human Performance Laboratory. While the rats were
still anesthetized, two, l-cm pieces of Alliedsil® silicone
tubing (I.D. 0.078"; Allied Biomedical, Paso Robles, CA)
were implanted in the subcutaneous region between the
scapulae. In halfthe rats (the androstenedione group, n
= 13), the silicone tubing contained 100 mg androstenedione plus filler (99.5% purity, ratio to filler 1:10;
Ultimate Nutrition®, Inc., Farmington, CT) which delivered approximately 1 f..lg androstenedione per gram
body weight per day for 8 weeks. The delivery rate was
calculated based on the manufacturer's recommended
daily dosage of androstenedione for adult humans. The
ends of the silicone tubing were secured with a small
piece of a wooden dowel and medical implant grade RTV
adhesive (Applied Silicone Corp., Ventura, CA). The
remaining rats (the control group, n = 13) were implanted with two, 1 cm pieces of silicone tubing which
contained an equal quantity of dextrose. The rats were
maintained on normal Purina rat chow and water ad
libitum and weighed weekly.
Eight weeks following implantation of the silicone
tubing, animals were anesthetized as previously described and the left femoral artery was exposed. A
catheter, constructed from a 6 cm piece ofTeflon®tubing
(I.D. 0.015"; Small Parts, Inc., Miami, FL) inserted into
a 25 cm piece ofTygon® tubing (I.D. 0.02"; Cole-Parmer,
Vernon Hills, IL), was placed in the femoral artery. The
catheter was secured to the artery with 3-0 silk ties,
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tunneled dorsally beneath the animal's skin, exited at
the base of its neck, and secured with a surgical tether
button (Harvard Apparatus, Holliston, MA). Following
surgery, the animal was returned to its home cage, given
normal rat chow and water ad libitum, and weighed
daily. All animals were given 2 days to recover from
surgery.

the skull of the rat and selecting the "total" measure of
BMD for the region. Cardiovascular data were analyzed
by ANOVA with statistical significance ascribed for p <
0.05. Body weights, organ weights, BMD, and plasma
cholesterol, cortisol, and testosterone were analyzed
using a two-tailed, unpaired t-test with statistical significance ascribed for p < 0.05.

Following recovery from surgery, the animals remained in their home cages for a 30 minute measurement of resting mean arterial pressure (MAP) via a
computerized data acquisition system (MacLab®, CB
Sciences, Inc., Milford, MA). At the end of the 30 minute
period, a 2.5 ml blood sample was slowly withdrawn
from the arterial catheter and placed in a chilled
microfuge tube containing 10 JlI EDTA (90 mg/ml
ethyleneglycol-bis[~-animoethyl ether] N,N,N",N"tetraacetic acid, Sigma No. E-4378). The sample was
centrifuged for 5 minutes at 2500 rpm, and the plasma
was transferred to a clean microfuge tube and stored at
-80 ·C. The formed elements of the blood were resuspended in heparinized isotonic saline (67 USP units/ml)
to a volume equaling 2.5 ml and returned to the animal.

RESULTS

The following day the animals were exposed to a
novel, mild, physical stress, which consisted of being
placed in a plastic 5-gallon bucket containing shoulderdeep 37 ·C water for 15 minutes. MAP was measured as
previously described for 15 minutes before the stress
while the animal remained in its home cage, during the
immersion stress, and for 15 minutes immediately after
the stress when the animal was returned to its home
cage. A 0.5 ml blood sample was taken before, immediately after, and 15 minutes after exposure to the immersion stress. The volume of the blood sample was immediately replaced with isotonic saline. The blood samples
were treated as previously described, except that the
formed elements of the blood were not returned to the
animal.
The following day the animals were euthanized with
an overdose of ether and the carcasses stored at -80 ·C.
Following collection of cardiovascular data and plasma
samples from all animals, the carcasses were thawed
and a second measure of BMD was made as previously
described. In addition, the heart, liver, kidneys, adrenal
glands, and ovaries were excised and weighed.
Plasma cholesterol was measured using an enzymatic, colorimetric assay (procedure 352, Sigma Diagnostics, St. Louis, MO). Plasma cortisol and testosterone were measured using radioimmunoassay (procedures 07-121002 and 07-189002, respectively, ICN
Biochemicals, Inc., Costa Mesa, CA). All samples for
each particular assay were processed simultaneously.
Bone mineral density was analyzed by highlighting

There were no significant differences in body weight
between the control group and the androstenedione
group at any time during the study (Fig. 1). In addition,
there were no significant differences in MAP between
the control group and the androstenedione group during
rest (Fig. 2) or during the stress session (Fig. 3). MAP
was significantly elevated from rest within both groups
during the immersion stress and throughout the recovery period, but there were no MAP differences within
either group between the stress and recovery periods
(Fig. 3). Plasma cortisol levels were not significantly
different between groups during any of the sampling
periods, although plasma cortisol was significantly elevated during the recovery period compared to the prestress period within the control group (Fig. 4).
There were no significant differences in organ weights
or BMD between groups (Table 1), although BMD was
significantly higher at the end of the study in both
groups. Moreover, there was no significant difference in
plasma testosterone at rest between groups (Table 1).
Plasma cholesterol (total), however, was significantly
lower in animals in the androstenedione group compared to animals in the control group (Table 1).

DISCUSSION
The major limitation of this study was that circulating levels of androstenedione were not evaluated, so any
conclusions about the potential influence of androstenedione on the parameters in question are suspect.
Plasma androstenedione can be measured using radioimmunoassay, but, unlike the radioimmunoassay procedures for measurement of testosterone and cortisol
which utilize 3H, the procedure for measurement of
androstenedione utilizes 1251. Data concerning circulating levels of androstenedione would, of course, permit
conclusions to be based on the potential influence of
androstenedione. The primary investigator's institution is not licensed to use this isotope, so evaluation of
circulating levels of androstenedione was not possible.
It is entirely possible that the implants became encased
with subcutaneous fat or, for some other reason, failed to
deliver androstenedione at the desired dosage (or at all).
Moreover, since the animals were not ovariectomized, it
is also possible that any increase in plasma androstenedione was offset by a decrease in ovarian activity.
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Figure 1. Weekly body weights offemale Long Evans rats. Rats in the andro group (n =13) were treated with androstenedione
(surgical implant to deliver 111g androstenedione per gram body weight daily for 8 weeks) whereas animals in the control group
(n = 13) were treated with dextrose. Week 1 represents weight on day implant was surgically put in place. Values expressed as
mean ± standard deviation.
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Figure 2. Mean arterial pressure offemale Long Evans rats during a 30 minute home cage rest session. Rats in the andro group
(n = 13) we11! treated with androstenedione (surgical implant to deliver 111g androstenedione per gram body weight daily for 8
weeks) whereas animals in the control group (n =10) were treated with dextrose. Values expressed as mean ± standard deviation.
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Therefore, plasma androstenedione levels may have not
been different between groups.
The only significant difference observed between
groups was the lower level of total plasma cholesterol in
the androstenedione group. This is consistent with the
general observations of other investigators (King et al.
1999), who demonstrated that long term treatment with
androstenedione lowered serum high-density lipoprotein cholesterol levels. Again, due to limitations in the
resources available to the primary investigator, only
total plasma cholesterol and not the lipoprotein profile of
these animals was measured in this study. If the lower
total plasma cholesterol level reflects a decrease in lowdensity or very-low density lipoprotein cholesterol levels, this would suggest that the treatment was beneficial
to the cardiovascular system. If the lower total plasma
cholesterol level reflects a decrease in high-density lipoprotein cholesterol levels, however, then the treatment
would be considered to be potentially deleterious to the
cardiovascular system.
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The results of this study demonstrated no influence
on the cardiovascular activity in sedentary female Long
Evans rats at rest or during exposure to novel stress.
While testosterone may have a direct role in the increased risk of cardiovascular disease observed in males
(Adams et al. 1995, Bruck at al. 1997), short-term
administration of testosterone has been shown to have
relaxing effects on coronary arteries in both animals
(Chou et al. 1996, Yue et al. 1995) and humans (Webb et
al. 1999). Again due to the limitations of the study, it is
not possible to conclude that long-term administration
of androstenedione influences cardiovascular activity.
There were no differences in plasma levels of testosterone and cortisol between groups in this study. King
et al. (1999) and Wallace et al. (1999) reported no
increases in plasma levels of testosterone in response to
acute ingestion of androstenedione. While significant
increases in serum estradiol and estrone levels have
been observed following long-term (8 weeks) androstenedione supplementation (King et al. 1999), no increases in serum testosterone were observed. While no
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Figure 3. Mean arterial pressure offemale Long Evans rats during a novel stress (15-minutes immersion in shoulder-deep 37°C
water) session. Rats in the andro group (n = 13) were treated with androstenedione (surgical implant to deliver 1 IJ.g
androstenedione per gram body weight daily for 8 weeks) whereas animals in the control group (n =10) were treated with dextrose.
Minutes 5-15 represent a 15 minute home cage pre-stress period, minutes 20-30 represent the 15 minute stress period, and
minutes 35-45 represent a 15 minute home cage recovery period. Values expressed as mean ± standard deviation. *Significantly
different from pre-stress period within group, p < 0.05.
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previous work has been done examining the influence of
long-term treatment with androstenedione on plasma
cortisol levels, the limitations ofthe present study do not
permit any conclusions on the influence of androstenedione supplementation on plasma cortisol levels.
There were no differences in body weight between
groups in this study. While this observation is relatively
consistent with the results of other investigators (King
et a1. 1999, Wallace et a1. 1999) who reported that long
term androstenedione supplementation failed to enhance lean body mass in males, the limitations of the
study do not permit any conclusions about the influence
ofandrostenedione on either body composition or growth
in female subjects. In addition, there were no differences
in organ weights between groups. Long term anabolic
steroid use is associated with hypertrophy of the heart
and atrophy of the gonads (National Institute on Drug
Abuse Research Report Series, 2000), and the liver and
kidneys must metabolize and excrete waste products,
respectively, from supplemental steroids. Again, due to
the limitations of this study, no conclusions about the

influence of supplemental androstenedione on organ
function are possible.
Bone mineral density was significantly greater in
both groups at the conclusion ofthe study compared with
the beginning of the study, but the animals were only 10
weeks of age at the beginning of the study, so this
increase in BMD is consistent with the normal changes
in BMD associated with growth. While previous work
suggests that supplemental androstenedione can protect against osteopenia (Lea and Flanagan 1998) and
that postmenopausal women with higher androgen levels have greater bone mass (Murphy et a1. 1992), the
results of this study do not indicate any influence on
peak bone mass development.
In summary, the inability to measure circulating
levels of androstenedione in both groups of animals
severely impacts the ability to make any conclusions
concerning the influence of long term androstenedione
treatment on plasma testosterone, cortisol, and cholesterol, MAP, BMD, body weight, and organ weights in
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Table 1. Body weight at time of surgery, organ weights, bone mineral density (BMD), and resting levels of plasma testosterone
and cholesterol of female Long Evans rats. Rats in the androstenedione group (n = 13) were treated with androstenedione
(surgical implant to deliver 1 J.l.g androstenedione per gram body weight daily for 8 weeks) whereas animals in the control group
(n =13 except for plasma data where n =10) were treated with dextrose. Values are expressed as mean ± standard deviation.

Androstenedione group

Control group

315.9±24.9

309.8± 21.0

871± 80

879± 88

Liver (g)

11.978 ± 0.686

11.763 ± 1.777

Kidneys (g)

2.339 ± 0.172

2.352 ± 0.297

Adrenal glands (mg)

92± 13

83± 14

Ovaries (mg)

85±20

87± 19

0.314 ± 0.032

0.315 ± 0.025

BMD (final) (g/cm2)

0.378 ± 0.035#

0.364 ± 0.031#

Plasma testosterone (ng/ml)

0.0851 ± 0.0150

0.0836 ± 0.0085

78.1 ± 52.4

141.9 ± 89.5*

Body weight (g) at surgery
Heart (whole) (mg)

BMD (initial)

(g/cm2)

Plasma cholesterol (total; mg/dl)

* Statistically different from androstenedione group, p < 0.05.
# Statistically different from initial BMD measure, p < 0.05.
female rats. Given that most of the information concerning the effects oflong term androstenedione treatment
focus on the influence of this supplement on male subjects, further investigation of the effects of androstenedione on female subjects is warranted.
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